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BACKGROUND
OBJECTIVE
• To assess predictors of prescription opioid use in a community-based cohort of 
middle-aged and older adults with a high prevalence of chronic pain. 
METHODS
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• Despite declining opioid prescribing rates in the United States, the annual 
prevalence of prescription opioid use in adults ≥50 years old is estimated to be 
40%, higher than that of younger adults (ages 18-29 years, 36%).
• In addition, opioid misuse among adults ≥65 years old is increasing, which is 
particularly concerning given their higher prevalence of chronic pain and 
vulnerability to opioid-related harms (i.e., falls, unintentional overdose).
• As the American population ages, understanding factors that contribute to 
overall opioid use is a necessary first step in the determination and mitigation 
of inappropriate prescribing and opioid-related harms.
METHODS
Study Participants & Data Collection 
• This study included participants from the Johnston County Osteoarthritis 
Project (JoCoOA), a community-based longitudinal cohort study of residents in 
predominantly rural Johnston County, North Carolina.
• JoCoOA enrolled a representative sample of African American (AA) and White 
civilian adults aged ≥45 years, regardless of osteoarthritis status (T0: n=3,187, 
T1* enrichment: n=1,015); follow-up occurred approximately every 5 years.
• Participants included in the analysis (n=786) completed consecutive T2 and T3 
follow-up visits, were not missing T2 or T3 medication data, and did not report 
using prescription opioids at T2. 
Statistical Analysis
• Univariable logistic regression was used to estimate odds ratios (OR) and 95% 
confidence intervals (CIs) for the crude association between each variable and 
opioid use. Variables significantly associated with opioid use in univariable 
models (p<0.05) were included in a multivariable logistic regression model to 
estimate adjusted ORs (aOR) and 95% CIs. 
• Among 786 JoCoOA participants who were non-opioid users at baseline:
• 66 years old on average [standard deviation=7.4; range=50-88]
• 67% women, 31% AA, 55% obese based on BMI
• 20% with history of depressive symptoms, 46% felt bothered at least 
“once in a while” by a lack of social support
• 28% reported having catastrophic thoughts related to pain
• Polypharmacy was prevalent in 51% of participants
• At follow-up, 13% (n=100) of participants were using prescription opioids
• Significant independent predictors of opioid use included: younger age, 
high pain catastrophizing, polypharmacy, and a history of depressive 
symptoms. 
Potential Predictors of Opioid Use (T2; 2006-2010) 
Opioid Use (T3; 2013-2015) 
• Ascertained from T3 medications questionnaire, where medication names for 
all prescription and OTC medications used on regular or as-needed basis were 
documented by research staff. 
• Medication names reviewed for generic and brand name opioid analgesics: 
codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, 
morphine, oxycodone, oxymorphone, tramadol.
• Contributing to the fundamental opioid research that is needed
on middle-aged and older adults, the simultaneous assessment
of a breadth of clinical and sociodemographic factors identified
polypharmacy, pain catastrophizing, and depressive symptoms
as modifiable predictors of prescription opioid use.
• Among patients ≥50 years old with chronic pain, our results
support: 1) assessing these factors during clinical encounters
and 2) providing alternative treatment approaches, such as
behavioral interventions and pharmacological review.
CONCLUSIONS
RESULTS
Participant Characteristica Opioid Use No Opioid Use Univariable Models Multivariable ModelOR (95% CI) p-value aOR (95% CI) p-value
Age (years), n (%)
50–60 30 (17.2) 144 (82.8) 2.23 (1.22, 4.08) 0.009 2.52 (1.08, 5.88) 0.033
60–69 50 (13.2) 328 (86.8) 1.63 (0.94, 2.82) 0.079 1.70 (0.87, 3.33) 0.119
≥70 20 (8.5) 214 (91.5) ref. ref.
Sex, n (%)
Male 24 (9.3) 235 (90.7) ref. ref.
Female 76 (14.4) 451 (85.6) 1.65 (1.02, 2.68) 0.043 1.27 (0.72, 2.24) 0.406
Race, n (%)
White 65 (11.9) 480 (88.1) ref.
African American 35 (14.5) 206 (85.5) 1.26 (0.81, 1.95) 0.315
Body Mass Index, n (%)
< 30 kg/m2 28 (7.9) 328 (92.1) ref. ref.
≥ 30 kg/m2 72 (16.7) 358 (83.3) 2.36 (1.49 , 3.74) <0.001 1.59 (0.95, 2.67) 0.079
Educational Attainment, n (%)
≥ 12 years 82 (12.1) 594 (87.9) ref.
< 12 years 18 (17.1) 87 (82.9) 1.50 (0.86, 2.62) 0.155
Employment Status, n (%)
Employed/Retired 75 (10.9) 612 (89.1) ref. ref.
Unemployed 25 (26.3) 70 (73.7) 2.92 (1.74, 4.88) <0.001 1.31 (0.65, 2.62) 0.453
Household Poverty Rate, n (%)
<12% 30 (10.1) 266 (89.9) ref.
12%–24% 51 (13.4) 329 (86.6) 1.37 (0.85, 2.22) 0.193
≥25% 19 (17.3) 91 (82.7) 1.85 (0.99, 3.45) 0.052
Marital Status, n (%)
Married 53 (10.8) 440 (89.2) ref.
Unmarriede 41 (15.6) 222 (84.4) 1.53 (0.99, 2.38) 0.056
Depressive Symptoms, n (%)
No 56 (9.1) 561 (90.9) ref. ref.
Yes 44 (27.8) 114 (72.2) 3.87 (2.48, 6.02) <0.001 2.00 (1.17, 3.43) 0.012
Social Support, n (%)
Strong 39 (9.5) 371 (90.5) ref. ref.
Moderate/Poor 56 (15.9) 296 (84.1) 1.80 (1.16, 2.78) 0.008 1.24 (0.76, 2.04) 0.385
Pain Catastrophizing, n (%)
Normal 47 (8.6) 502 (91.4) ref. ref.
High 51 (23.1) 170 (76.9) 3.20 (2.08, 4.94) <0.001 2.17 (1.33, 3.56) 0.002
Pain Sensitivity, n (%)
Normal 59 (10.5) 503 (89.5) ref.
High 35 (18.0) 159 (82.0) 1.88 (1.19, 2.96) 0.007 1.24 (0.72, 2.13) 0.436
Health Insurance, n (%)
Private 30 (8.9) 307 (91.1) ref. ref.
Public 46 (18.0) 209 (82.0) 2.25 (1.38, 3.69) 0.001 1.38 (0.78, 2.46) 0.270
Uninsured 22 (12.3) 157 (87.7) 1.43 (0.80, 2.57) 0.225 1.26 (0.63, 2.49) 0.513
Polypharmacy, n (%)
0–4 Medications 26 (6.7) 360 (93.3) ref. ref.













2001 2003 2009 2013 201520072005
T1*
(2003-
2004) T2 (2006-2010) T3 
(2013-2015)
T1 (1999-2004)
Visit 1 Visit 2 Visit 3
1999 2011




1990 1995 2000 20102005 2015
Enrich T1*
2003-2004
Baseline Assessment of 
Sociodemographic and Clinical 




Self-Reported Variables: age, sex, race, employment status, educational attainment
(years of formal schooling), marital status (unmarried includes never married,
separated, divorced, widowed), insurance status
BMI body mass index, computed from measured height, weight
Household 
Poverty Rate
percentage of households in a Census block group with income 




participant report of doctor, nurse, health professional telling them 
they have/ever had depression and/or score≥16 on the Center for 
Epidemiologic Studies Depression Scale (CES-D; range 0-60) 
Perceived
Social Support
quantified with Strong Ties Measure of Social Support (range 0-
20); moderate/poor[<19], strong[≥19] 
Pain 
Catastrophizing
an exaggerated negative cognitive state that arises in response to 
actual/anticipated pain, measured with the Pain Catastrophizing 
Helplessness Subscale (range 0-25); high[≥15], moderate/low[<15]
Pain Sensitivity 
operationalized as pressure-pain threshold (PPT) measured during 
T2 visit using a mechanical pressure-based dolorimeter; 
sensitive[<4kg], normal[≥4kg]
Polypharmacy
≥5 medications, determined using T2 medications questionnaire; 
participants showed research staff all prescription and over-the-
counter (OTC) medications used on regular or as-needed basis
a All percentages are row percentages, out of the total number of participants within the category of each characteristic
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